share_log

Roth Capital Reinstates Buy on Rain Oncology, Announces $21 Price Target

Roth Capital Reinstates Buy on Rain Oncology, Announces $21 Price Target

罗斯资本恢复对Rain Oncology的买入,宣布目标股价为21美元
Benzinga Real-time News ·  2023/01/31 08:34

Roth Capital analyst Kumaraguru Raja reinstates Rain Oncology (NASDAQ:RAIN) with a Buy and announces $21 price target.

罗斯资本分析师库马拉古鲁·拉贾恢复了Rain Oncology(纳斯达克股票代码:RAIN)的买入,并宣布了21美元的目标股价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发